p.40 抽出テキスト

Arnett et al 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

Circulation. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678 September 10, 2019 e635 CLINICAL STATEMENTS AND GUIDELINES

S4.5-24.	 Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Public Health Consequences of E-Cigarettes. Available at: http://nationalacademies.org/hmd/Reports/ 2018/public-health-consequences-of-e-cigarettes.aspx; 2018. Accessed January 5, 2019. S4.5-25.	 Ahmed AA, Patel K, Nyaku MA, et al. Risk of heart failure and death after prolonged smoking cessation: role of amount and duration of prior smoking. Circ Heart Fail. 2015;8:694–701. S4.5-26.	 Khan RJ, Stewart CP, Davis SK, et al. The risk and burden of smoking related heart disease mortality among young people in the United States. Tob Induc Dis. 2015;13:16. S4.5-27.	 NAADAC, the Association for Addiction Professionals. National Certificate in Tobacco Treatment Practice (NCTTP). Available at: https://www.naadac.org/NCTTP. Accessed January 5, 2019. S4.5-28.	 Association for the Treatment of Tobacco Use and Dependence (ATTUD). Available at: http://www.attud.org. Accessed January 5, 2019. S4.5-29.	 Council for Tobacco Treatment Training Programs. Accredited programs. Available at: http://ctttp.org/accredited-programs. Accessed January 30, 2019. S4.5-30.	 Otsuka R, Watanabe H, Hirata K, et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA. 2001;286:436–41. S4.5-31.	 Oono IP, Mackay DF, Pell JP. Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf). 2011;33:496–502. S4.5-32.	 US Institute of Medicine Committee on Secondhand Smoke Exposure and Acute Coronary Events. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: National Academies Press. 2010. Available at: http://www.ncbi. nlm.nih.gov/books/NBK219565. Accessed January 5, 2019. S4.5-33.	 US Department of Health and Human Services. The health consequences of smoking–50 years of progress: A report of the Surgeon General. ed. Atlanta, GA: 2014. S4.5-34.	 Tobacco Control Legal Consortium, Public Health Law Center. HUD’s

rule to restrict smoking in public housing: an overview. Available at: https://publichealthlawcenter.org/sites/default/files/resources/HUD- Final-Rule-Smoke-Free-Public-Housing-2016.pdf. 2017. Accessed January 5, 2019.

4.6 Aspirin Use

S4.6-1.	 Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2016;164:804–13. S4.6-2.	 Whitlock EP, Burda BU, Williams SB, et al. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2016;164:826–35. S4.6-3.	 Lotrionte M, Biasucci LM, Peruzzi M, et al. Which aspirin dose and preparation is best for the long-term prevention of cardiovascular disease and cancer? Evidence from a systematic review and network meta-analysis. Prog Cardiovasc Dis. 2016;58:495–504. S4.6-4.	 Raju N, Sobieraj-Teague M, Bosch J, et al. Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med. 2016;129:e35–6. S4.6-5.	 Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41. S4.6-6.	 Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. S4.6-7.	 Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–8. S4.6-8.	 Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary

prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510–20. S4.6-9.	 McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardio-

vascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–18. S4.6-10.	 García Rodríguez LA, Martín-Pérez M, Hennekens CH, et al. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS ONE. 2016;11:e0160046. S4.6-11.	 Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134:1579–94. S4.6-12.	 Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60. S4.6-13.	 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81. S4.6-14.	 Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388–91. S4.6-15.	 Bibbins-Domingo K, US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:836–45. S4.6-16.	 ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–39. S4.6-17.	 Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–46. S4.6-18.	 Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694–701. S4.6-19.	 Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol. 2014;64:319–27. S4.6-20.	 Mora S, Manson JE. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern Med. 2016;176:1195–204. S4.6-21.	 Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7:453–60. S4.6-22.	 Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392:387–99. S4.6-23.	 Ridker PM. Should aspirin be used for primary prevention in the

post-statin Era? N Engl J Med. 2018;379:1572–4.

5 COST AND VALUE CONSIDERATIONS

S5-1.	 Weintraub WS, Daniels SR, Burke LE, et al. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011;124: 967–90. S5-2.	 Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state-

ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–45.

Downloaded from http://ahajournals.org by on October 7, 2026